Somatostatin inhibits pancreatic exocrine secretion centrally via sympathetic nerves in conscious rats.
Somatostatin is known to be a potent inhibitor of pancreatic exocrine secretion, but the mechanism of its effect is not fully understood. The mechanism of the inhibition by centrally administered somatostatin was examined in conscious rats. Rats were prepared with cannulae draining bile and pancreatic juice separately, and with a duodenal cannula, an extrajugular vein cannula and a cerebroventricular cannula. Somatostatin was injected into the left lateral ventricle, and the inhibitory mechanism was examined using vagotomized rats and various drugs that affect sympathetic neurons. Intracerebroventricular administration of somatostatin significantly inhibited pancreatic exocrine secretion stimulated by bile-pancreatic juice diversion. The inhibitory effect was not abolished by vagotomy, pretreatment with propranolol, but was abolished by pretreatment with hexamethonium or phentolamine. The plasma level of somatostatin after its intracerebroventricular administration increased 3-fold, but its intravenous infusion at a rate giving a similar plasma somatostatin level to that produced by its intracerebroventricular injection, had no significant effect on pancreatic secretion. These results suggest that somatostatin inhibits pancreatic exocrine secretion centrally via sympathetic efferent nerves and that alpha-adrenergic receptors have an important role in its inhibitory action.
Masuda
M
M
Department of Clinical Physiology, Tokyo Metropolitan Institute of Gerontology, Japan.
Kanai
S
S
Miyasaka
K
K
Funakoshi
A
A
D000818:Animals; D007278:Injections, Spinal; D008297:Male; D010179:Pancreas / Q000187:drug effects*; D010646:Phentolamine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D013004:Somatostatin / Q000494:pharmacology*; D013564:Sympathetic Nervous System / Q000187:drug effects*
D013004:Somatostatin; D011433:Propranolol; D010646:Phentolamine